![]() |
|
|
Vol. 290, Issue 3, 1427-1435, September 1999
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts
| |
Abstract |
|---|
|
|
|---|
The activation of presynaptic histamine 3 (H3) receptors
inhibits the release of histamine and other neurotransmitters from central nervous system neurons. Rat brain mast cells (MCs) release histamine and 5-hydroxytryptamine (5-HT) in response to neuropeptides and neurotransmitters secreted from adjacent neurons. Dura MCs also
degranulate in response to antidromic trigeminal nerve stimulation and
with acute psychological stress. Such findings have implicated brain
MCs in certain neuroinflammatory disorders, such as migraines. We
investigated the ultrastructural appearance of control and stimulated
thalamic/hypothalamic (brain) MCs before and after treatment with the
H3 receptor agonist
N
-methylhistamine (N
-mH)
and the H3 receptor antagonist thioperamide (Th).
Ultrastructural investigation of brain MCs stimulated with compound
48/80 revealed extensive intragranular changes that paralleled 5-HT
secretion but without degranulation by exocytosis typical of connective tissue MCs. N
-mH significantly reduced these
morphological changes, as well as 5-HT release from brain MCs and
neurons stimulated with KCl; conversely, Th augmented both histamine
and 5-HT release from brain neurons and MCs. Neither
N
-mH nor Th had any effect on peritoneal MCs.
Simultaneous addition of both drugs largely antagonized each other's
effects on brain MC activation and 5-HT secretion. Ultrastructural
observations and lack of lactic dehydrogenase release in the perfusate
excluded any cytotoxic effect. The ability of H3 agonists
to inhibit brain MC activation, as well as secretion of 5-HT from both
brain MCs and neurons, may be useful in the management of migraines.
| |
Introduction |
|---|
|
|
|---|
Presynaptic
H3 receptors are present perivascularly in the
central nervous system (CNS; Ishikawa and Sperelakis, 1987
; Hill, 1990
). Their activation leads to autoinhibition of histamine (Arrang et
al., 1983
), 5-hydroxytryptamine (5-HT; Fink et al., 1990
;
Schlicker et al., 1988
; Oishi et al., 1990
), norepinephrine (Schlicker
et al., 1989
), and dopamine (Oishi et al., 1990
) secretion and prevents the development of "neurogenic inflammation" (Matsubara et al., 1992
). The H3 receptor agonists are histamine
derivatives in which a methyl group has substituted the hydrogen atoms
at the side chain of histamine or its analogs (Hill, 1990
).
R
-methylhistamine
(R
-mH) and
N
-methylhistamine
(N
-mH) are potent neuronal
H3 receptor agonists that inhibit histamine synthesis and release via activation of presynaptically located autoinhibitory receptors (Arrang et al., 1983
). Conversely,
H3 receptor antagonists potentiate neuronal
histamine release (Arrang et al., 1983
). The meninges and the
thalamic-hypothalamic area account for as much as 90% of all brain
histamine, almost 50% of which appears to be in mast cells (MCs)
(Goldschmidt et al., 1985
; Pollard et al., 1976
). However, the effect
of H3 receptor-active drugs on these cells has
not been investigated.
MCs derive from the bone marrow and acquire different morphological and
secretory characteristics under microenvironmental conditions (Galli,
1993
). In the brain, MCs are located at strategic points around
capillaries and small blood vessels, where they could regulate the
extent of cerebrovascular tone, as well as the permeability of the
blood-brain barrier (Theoharides, 1990
). MCs are best known for their
involvement in allergic reactions where bridging of specific surface
binding proteins for IgE (Fc
RI) leads to secretion of multiple
mediators; these include histamine, kinins, prostaglandin
D2, vasoactive intestinal peptide, tumor necrosis
factor (TNF), and nitric oxide, which are vasodilatory; they also
secrete 5-HT, prostaglandin F2
, and
leukotrienes that are vasoconstrictive (Theoharides, 1996
). Moreover,
histamine, kinins, prostaglandins, and proteolytic enzymes can cause
pain, whereas TNF and other cytokines can induce the expression of
intercellular adhesion molecules (Klein et al., 1989
). In addition to
immunological stimulation, MCs are activated by neurotransmitters such
as acetylcholine (Dimitriadou et al., 1990
), neuropeptides (Marathias
et al., 1991
), antidromic trigeminal nerve stimulation (Dimitriadou et
al., 1991
), and acute psychological stress (Theoharides et al., 1995
).
As a result, brain MCs are increasingly recognized as being potentially significant in CNS pathophysiology (Theoharides, 1996
; Kines and Powell, 1997
). We, therefore, investigated the effect of
H3-active drugs on rat brain and on peritoneal MC activation.
| |
Experimental Procedures |
|---|
|
|
|---|
Animals and Materials
Male Sprague-Dawley rats weighing approximately 300 g were purchased from Taconic, Inc. (Germantown, NY) and were kept three per cage in plastic, wire-top cages in an animal facility supervised by veterinarians. They were kept in a 24-h light/dark cycle and were provided food and water ad libitum. All efforts were made to minimize animal suffering.
Triton X-100 was obtained from New England Nuclear (Boston, MA). The
scintillation Ready Fluor III cocktail was purchased from Beckman
Instruments, Inc. (Fullerton, CA). Metrizamide was from Accurate
Chemical and Scientific Corp. (Westburg, NY). Dextrose and
paraformaldehyde were obtained from Fisher (Pittsburgh, PA). Imipramine
(IMI) was a gift from Ciba Pharmaceutical Co. (Summit, NJ). Compound
48/80 (C48/80) was purchased from Sigma Chemical Co. (St. Louis, MO).
Toluidine blue was obtained from Aldrich Chemical Co. (Milwaukee, WI).
Glutaraldehyde was purchased from EM Sciences (Fort Washington, PA).
Cacodylate HCl buffer, tannic acid, osmium tetroxide
(OsO4), propylene oxide, epoxy resin, hardener, and uranyl acetate were obtained from Polysciences, Inc. (Wallington, PA). N
-mH was purchased from Calbiochem Corp.
(La Jolla, CA). Thioperamide (Th) was a gift from Dr. M. Moskowitz (Massachusetts General Hospital, Harvard Medical
School, Boston, MA). All other chemicals used were of analytical grade.
Perfusion System
A four-well, customized perfusion chamber was used to allow
simultaneous investigation of four different conditions (Lambracht-Hall et al., 1990
). The volume of each well was 1 ml and was optimal for the
collection of sufficient brain perfusate to detect 5-HT and histamine.
The top and bottom parts of the perfusion chamber were sealed with
rubber o-rings and were held in place with four adjustable
bolts. Air vents at the top of the wells were used to purge entrapped
air and were also sealed by screws. The Plexiglas chamber wells were
separated with coverslips from steadily circulating water maintained at
37°C. The temperature of the perfusion solutions was also held at
37°C by a standard circulating water bath. The brain slices were
perfused by a four-channel microprocessor pump (MCP 2500; Buchler,
Saddle Brook, NJ). To avoid artificial changes in the concentration of
the released mediators by occasional air bubbles in the tubing, all
solutions were first passed through four in-line air traps. The
perfusion solution then entered at the top of each well, bathed the
tissue sitting on a round Teflon mesh filter (1 mm pore size), and
exited at the bottom of the chamber to a four-line simultaneous
fraction collector (1500 RTR VII; ISCO Lincoln, NE).
Preparation of Brain Samples
Rats were decapitated, and the skull was opened through the
midline. The brain was rapidly removed and put into cold oxygenated Krebs-Ringer-bicarbonate buffer (KRB; Lambracht-Hall et al., 1990
) containing 118.0 mM NaCl, 4.85 mM KCl, 1.15 mM
KH2PO4, 1.15 mM MgSO4, 25.0 mM NaHCO3, 2.5 mM CaCl2, and 11.1 mM dextrose, at pH 7.4. The
thalamic and hypothalamic areas were isolated and cut manually into
slices of approximately 1.5 × 1.5 × 0.5 mm using disposable
microblades in a cold room. The slices were then introduced together
into cold oxygenated KRB at 4°C and were used as described below.
5-HT and Histamine Release from Perfused Brain Tissue
[3H]5-HT (specific activity, 25.4 Ci/mmol [3H]5-HT; 5 × 10
7 M) was added to the pooled brain slices,
which were then incubated in 37°C for 15 min. The slices were then
washed four times with 40 ml of KRB containing
10
6 M IMI to prevent 5-HT reuptake
(Lambracht-Hall et al., 1990
). The presence of
10
6 M IMI had no effect on peritoneal MC
secretion as previously reported (Lambracht-Hall et al., 1990
).
Approximately equal amounts of tissue by weight (455 ± 35 mg)
were randomly distributed into the four individually perfused wells.
The brain slices were initially perfused with KRB (pH 7.4) at a flow
rate of 5 ml/min for 40 min to reduce nonspecific background; the flow
rate was then reduced to 1 ml/min. All perfusion solutions were
continuously saturated with 95% O2/5%
CO2. After 12 min of slow wash, the tissue was perfused for 36 min with different dilutions of
N
-mH or Th to investigate any effect on MC
morphology or mediator release. The slices were then stimulated for 24 min with C48/80 (100 µg/ml), the classic MC secretagogue that has
been previously shown to require this high concentration for a
noncytotoxic effect on CNS MCs (Lambracht-Hall et al., 1990
), followed
by a 20-min wash with KRB. Subsequently, the tissue was perfused for 24 min by modified KRB containing 40 mM KCl and 82.8 mM NaCl to cause maximal neuronal depolarization of endogenous histamine and 5-HT (Atack
and Carlsson, 1972
). The perfusion was finished by KRB wash for 12 min.
Fractions of perfusate were collected every 4 min, and aliquots of 0.5 ml were mixed with 1.5 ml of scintillation fluid, vortexed, and counted
for radioactivity reflecting serotonin release in a
scintillation
counter. Other aliquots were used for determination of histamine release.
C48/80 was deemed selective for stimulation of MCs because 1)
stimulation of brain slices with C48/80 did not affect subsequent stimulation with high K+ (Lambracht-Hall et al.,
1990
); 2) C48/80 did not trigger release of neuropeptides expected to
be released from neurons (Marathias et al., 1991
); 3) C48/80 induced
5-HT release from thalamus (Goldschmidt et al., 1985
) and hypothalamus
(Pollard et al., 1976
), areas rich in MCs, but not from cerebellum,
which does not contain MCs (Lambracht-Hall et al., 1990
); 4) 5-HT
release from neurons was dependent on extracellular calcium (Verdiere
et al., 1975
; Subramanian and Mulder, 1976
), whereas secretion from
stimulated MCs was independent, as has been described for the action of
C48/80 on peritoneal MCs (Subramanian and Mulder, 1976
; Lambracht-Hall
et al., 1990
); 5) 5-HT secretion by C48/80 from thalamic-hypothalamic
slices was reduced by cromolyn, which inhibits MCs but not neurons
(Lambracht-Hall et al., 1990
); and 6) treatment with capsaicin, which
depletes peptidergic sensory neurons, had no effect on C48/80-induced
brain 5-HT release (Marathias et al., 1991
).
Histamine Assay
A commercially available histamine radioimmunoassay (RIA) kit
(Kabi-Pharmacia, Piscataway, NJ) was used under conditions in which
histamine could be detected. Because of high cross-reactivity of the
primary antihistamine antibody with the N
-mH
added in some experimental conditions, histamine was measured only when
N
-mH was not used, such as in control and
Th-treated samples. The level of detection of the radioenzymatic assay
(20 pg/ml) and that of HPLC (<50 pg/ml), both of which could
distinguish histamine from N
-mH, were not
sufficiently sensitive to detect histamine in brain slices.
Electron Microscopic Procedures
The perfused thalamic and hypothalamic slices or purified
homogeneic peritoneal MCs were fixed in modified Karnovsky's medium containing 3% glutaraldehyde, 2% paraformaldehyde, and 0.5% tannic acid in 0.1 M cacodylate HCl buffer (pH 7.3) for 4 h at room
temperature followed by 12 h at 4°C. The next day, the fixative
was decanted, and the tissue was washed five times over the period of
6 h in 0.1 M cacodylate HCl buffer (pH 7.3). Then, the samples
were osmicated with 1% OsO4 in 0.1 M cacodylate
HCl buffer (pH 7.3) for 2 h at room temperature. The tissue was
then washed with cacodylate HCl buffer and dehydrated in a graded
series of alcohol at 4°C, the last one consisting of absolute
alcohol, which was changed four times; 100% propylene oxide was added
and changed twice. For tissue impregnation, the Epon was prepared as
follows: 100% propylene oxide was added to an equal volume of epoxy
resin mixed with hardener. Infiltration was performed for 12 h at
room temperature. Embedded tissue was then put in 100% epoxy resin
with hardener and placed into a 56°C oven for 48 h. Next,
1-µm-thick sections were stained with 0.1% Toluidine blue (pH 2.5)
and MCs were first identified by light microscopy. Areas of interest
were selected and sections for electron microscopy were cut at
1000 Å and mounted on copper mesh grids. The sections were then
stained with 7.5% uranyl acetate in 50% alcohol and lead salts and
were examined with a Philips 300 Transmission Electron Microscope
(Dimitriadou et al., 1990
).
Electron Microscopic Morphometry
Brain MCs from each experimental group were photographed at a magnification ranging from 9600× to 16,000×. Each photograph contained a single MC at a magnification that allowed for individual evaluation of each secretory granule present. The total number of granules was also noted for the calculation of percentages represented by each group. Granules were categorized as intact or activated according to the following criteria:
Intact. Intact granule contents are uniform in density and lack any substructure or vacuoles.
Activated. Empty granules have little or no residual density present with empty vesicles ("honeycomb"). Partially empty granules have irregular density of granule contents with vacuoles or empty vesicles and contain "fibrillar material," which is granular contents of varying amount and density, usually less than that of normal granules, without homogeneous density.
Prints were examined by an investigator blinded to the experimental code and were scored into four categories as described above. Scores were then segregated into their appropriate experimental treatment group, and results are presented as percent of total.Peritoneal MC Purification and Amine Release
MCs were obtained from the peritoneal cavity of the same rats,
the brain of which was used for the perfusion experiments by lavage in
HEPES-buffered Locke's solution containing 150 mM NaCl, 5 mM KCl, 2 mM
CaCl2, 5 mM HEPES, 1 g/liter BSA, and 1 g/liter dextrose (pH 7.2). MCs were then purified (purity > 90%) over 22.5% metrizamide (350g for 10 min), washed three times in
Locke's solution (200g for 5 min), and then labeled with
[3H]5-HT (2 µCi/106
cells/2 ml) at 37°C for 45 min. After two washes, the cells were resuspended in Locke's solution. Aliquots of 105
cells/100 µl were then added to different concentrations of the H3 receptor ligands to be tested for 90 min, and
the cells were stimulated by 0.1 µg/ml C48/80 in the experiments with
N
-mH and 0.05 µg/ml in the experiments with
Th for an additional 10 min at 37°C as needed. The cells were then
centrifuged at 400g for 10 min, and 0.5 ml of supernatant
was added to 3 ml of scintillation fluid. The pellets were solubilized
with 0.5 ml of 2% Triton X-100 and added to 3 ml of scintillation
fluid as well. Radioactivity was determined in a
scintillation
counter. All four tissue samples were weighed at the end of every
experiment. Histamine was determined by the same RIA described above.
Viability
Viability was assessed according to the amount of lactic dehydrogenase (LDH) present in the perfusate using a commercially available kit (Sigma Chemical Co., St. Louis, MO).
Statistical Analysis
For mediator release from brain slices, the area under the curve (in counts per minute × minute) was calculated using trapezoidal areas between the experimental points. All data entry, formatting, calculations of area under the curve, statistical analysis, and graphing were done using a custom-designed program based on Excel with a Macintosh II cx computer. The data (in arbitrary units of counts per minute × minutes) were adjusted to eliminate differences in weight by dividing each perfused tissue sample by the average weight (in milligrams) value of all controls and all other samples taken together. Comparisons of results from experiments regarding 5-HT release from purified peritoneal MCs and from ultrastructural observations were made between the means of each condition using ANOVA. A value of p < .05 is considered statistically significant.
| |
Results |
|---|
|
|
|---|
Effects of Na-mH and Th on Rat Brain MC
Ultrastructure.
Perfusion of brain slices with KRB alone (control)
resulted in ultrastructural changes of about 14% of MC secretory
granules in 9% of studied MCs (Table 1
and Fig. 1). These control cells showed
the typical appearance of connective tissue MCs (CTMCs; Fig. 1) with
numerous round, homogeneous, electron-dense granules and an unlobulated
nucleus with peripherally clumped chromatin (Fig. 1). Stimulation with
C48/80, however, resulted in activation of 54% of secretory granules
in 42% of MCs (Table 1 and Fig. 2A). The
morphology of the granules in MCs activated by C48/80 was quite
striking and was distinct from classic degranulation, with typical
compound exocytosis seen in homogeneic peritoneal MCs stimulated by 0.1 µg/ml C48/80 (Fig. 3D). Instead, these
activated brain MCs showed altered granular content characterized by
partially filled or empty multivesicular secretory granules often with
a "honeycomb" structure (Fig. 2A). This appearance was very similar to that of MCs pretreated by both Th and N
-mH
before activation with C48/80 (Fig. 2B). Such changes were only
minimally present in unstimulated brain tissue (Fig. 1), suggesting
that they were not due to tissue incubation or preservation.
|
|
|
|
-mH (10
6 M)
significantly reduced (p < .05) granule activation
from 54% with C48/80 to 19% in 11% of MCs (Table 1, Fig.
4A), whereas the antagonist Th
(10
6 M) significantly increased
(p < .05) such activation to 68% (Table 1,
Fig. 4B). Th alone (10
6 M) increased
basal control brain MC activation from 14 to about 21% (results not
shown). When both drugs (N
-mH and Th) were
used simultaneously at equimolar concentrations, activation due to Th
was reduced to 37% (Table 1, Fig. 2B); neither drug was used in excess
of the other to investigate the possibility of complete reversal of
each other's effects. Neither N
-mH nor Th at
10
6 M had any effect on homogeneic
peritoneal MC activation either on their own (Fig. 3, B and C) or in
response to stimulation by C48/80 (Fig. 3, E and F).
|
5-HT Release from Brain Slices.
N
-mH
used on its own did not have any statistically significant effect on
5-HT release from brain slices in any of the concentrations used (Fig.
5). On the other hand, Th used at
10
6 M without any other stimulus significantly
(p < .00005) increased 5-HT release from about 42 to
almost 64% (Fig. 5). The addition of Th to
N
-mH (10
6 M
for both) reversed (p > .05 compared with control)
this increase (Fig. 5). These results imply there may be some tonal
inhibition of 5-HT release by endogenous histamine.
|
7 M N
-mH
(p < .0008), as shown in Fig.
6. On the contrary, Th
(10
6 M) significantly
(p < .0007) increased the release of 5-HT in the
presence of C48/80 to 102.2 ± 14.4 cpm/mg × min. This
increase is more than (p < .05) the amount released by
Th alone, which is almost equivalent to that of C48/80 alone,
indicating that Th augmented C48/80-induced 5-HT release. When Th
(10
6 M) was used along with
N
-mH (10
6 M)
in the perfusion, the drugs largely neutralized each other's effects
(Fig. 6). It should be noted that the effect of
N
-mH was not dose dependent and was
highest between 10
6 and
10
7 M.
|
-mH reduced neuronal 5-HT
secretion in all concentrations used (p < .05) but
maximally inhibited it to 39.6 ± 8.6 cpm/mg × min at
10
4 M (p < .003). Th
alone powerfully increased neuronal 5-HT secretion to 109.2 ± 26.9 cpm/mg × min (p < .0007), again indicating
tonal inhibition of neuronal secretion by histamine. Unfortunately, the
addition of both drugs was not done at varying concentrations. The
simultaneous presence of both N
-mH
(10
6 M) and Th
(10
6 M) in the perfusate buffer
largely neutralized each other's effects (Fig.
7).
|
Histamine Release from Brain MCs and Neurons.
The effect of
N
-mH on histamine release from brain slices
was difficult to assess because of high cross-reactivity of the primary
antihistamine antibody used in the RIA with the
N
-mH added in these experiments. Despite an
apparent decrease of histamine release in the
N
-mH-treated samples, the standard deviation
was still too high to make any meaningful statistical evaluation
possible. Determination of histamine radioenzymatically or by HPLC was
not sufficiently sensitive to detect the brain amine levels released in
the perfusate (results not shown).
6
M Th increased stimulation with 100 µg/ml C48/80 from
0.007 ± 0.002 to 0.012 ± 0.0034 ng/ml/mg × min/mg
(p < .05). The same was true for stimulation by
K+ (40 mM), where Th increased histamine release
from 0.006 ± 0.002 to 0.017 ± 0.004 ng/ml × min/mg
(p < .003). It was, therefore, evident that the
H3 receptor agonist reversed some tonal
inhibition of histamine on its own secretion from both the C48/80 and
high K+-sensitive sources.
|
5-HT and Histamine Release from Purified Rat Peritoneal MC.
The release of 5-HT from peritoneal MCs stimulated with C48/80 was not
affected by either the H3 receptor agonist
N
-mH (Fig. 9A)
or the antagonist Th (Fig. 9B). The same was true for histamine release
(results not shown).
|
Viability. Viability was assessed by the ultrastructural appearance of the cells and the lack of significant amounts, compared with controls, of LDH in the perfusate.
| |
Discussion |
|---|
|
|
|---|
Brain MCs are almost exclusively perivascular, often in close
contact with neurons (Dimitriadou et al., 1990
), and were characterized as CTMC because they contained histamine, rat mast cell protease I,
heparin, as well as mRNA for IgE-binding protein (Pang et al., 1996
).
Electron microscopic observations clearly indicated that the
H3 receptor-active agents affected brain MC
secretion. MC intragranular changes after stimulation with C48/80 were
increased in the Th-treated group but decreased when treated with
N
-mH. The ultrastructure of activated brain
MCs was unique in that it was not accompanied by typical exocytosis
with extrusion of granule contents outside the cell. Instead, affected
secretory granules showed a multivesicular substructure with or without electron-dense content. Such ultrastructural appearance could not be an
artifact of fixation because control brain MCs contained unaltered,
typical, electron-dense granules. Activated brain MCs with a similar
morphological appearance had previously been noted by us in response to
C48/80 or carbachol (Dimitriadou et al., 1990
), as well as by other
investigators (Ibrahim et al., 1979
). CTMC-like cells with
heterogeneous electron-dense granules and lipid bodies are also found
perivascularly. These neurolipomastocytes are distinct from other
granular cells (Dimitriadou et al., 1990
), and lipid bodies are
frequently seen in immature MCs (Dvorak et al., 1993
), where they may
be important for arachidonate metabolism.
The H3 receptor-active drugs used here had no
effect on peritoneal MC activation, as judged by ultrastructural
observations or amine secretion. Our results support previously
reported findings showing H3-active agents not to
have any effect on rat peritoneal (Kohno et al., 1994
; Stenton and Lau,
1997
) and lung (Dimitriadou et al., 1994
) MCs, as well as on human
adenoidal MC histamine secretion (Bent et al., 1991
). However, the
possibility remains that H3 agonists may affect
secretion of other mediators from extracranial MCs, as was shown for
TNF-
(Bissonnette, 1996
). The present results show that 5-HT
released from nonneuronal compartments by C48/80, presumably from brain
MCs, was reduced by the H3 receptor agonist
N
-mH, whereas both released 5-HT and histamine
were increased by the H3 receptor antagonist Th.
These findings suggest that brain H3 receptors
regulate the release of histamine and 5-HT from both neuronal and
nonneuronal sources. A similar inhibitory action on both
neurotransmitters had previously been reported but only for neurons
(Arrang et al., 1983
; Schlicker et al., 1988
; Oishi et al., 1990
).
Other physiologically relevant secretogogues, such as acetylcholine or
substance P, were not used here because their effects are not specific
for MCs. Despite the high amount required to penetrate the brain slices
due to its cationic nature, C48/80 had been shown to be a selective
secretagogue for brain MCs because it did not affect neuronal
secretion, was inhibited by cromolyn, and was not cytotoxic as judged
by ultrastructural appearance and lack of LDH in the perfusate
(Lambracht-Hall et al., 1990
). Even though C48/80 was reported to
induce release of monoamines from brain slices obtained from
W/Wv MC-deficient mice (Lovenberg and Cubeddu,
1988
), the amount of C48/80 used in that study was at cytotoxic levels
and cell viability had not been determined. Secretion of 5-HT from
brain slices was calculated as the area under the curve (Lambracht-Hall
et al., 1990
), whereas that from peritoneal MCs was expressed as
percent of total. This difference in calculation of the results was
necessitated because purified MCs, unlike brain slices, are the sole
source of histamine or [3H]serotonin. In
contradistinction, thalamic-hypothalamic MCs contribute about 50% of
total brain histamine and much less of 5-HT; in fact, histaminergic
neurons are known to exist in the rat hypothalamus (Panula et al.,
1984
). Early attempts at purifying brain MCs failed because they
degranulated during the process of purification.
N
-mH inhibited neuronal 5-HT secretion in
thalamic-hypothalamic slices over the concentration range of
10
6 to 10
8 M by a
maximum of about 30%, which is comparable with the 25% inhibition
reported for rat brain cortex (Schlicker et al., 1988
). However, no
dose-response relationship was evident for C48/80-induced, presumably
brain, MC secretion, which was also reduced by about 25% at
10
6 M. This discrepancy may be due to the low
affinity of N
-mH for H3
receptors on brain MCs, to the presence of only a few H3 receptors; to the possible existence of
H3 receptor subtypes (Leurs et al., 1996
),
possibly with low-affinity H3 receptor (West et
al., 1990
); or to a non-receptor-mediated effect. The lack of a
dose-response had previously also been reported for the inhibitory effect of the H1 receptor antagonist hydroxyzine
on histamine release from rat peritoneal MCs (Theoharides et al.,
1985
). H3 receptors have also been functionally
identified in the dura mater (Matsubara et al., 1992
), where MC
activation (Dimitriadou et al., 1991
) and vascular permeability
(Dimitriadou et al., 1992
) by trigeminal nerve stimulation were also
inhibited by presynaptic 5-HT receptor agonists (Buzzi et al., 1992
).
However, such inhibition did not occur in tongue MCs treated similarly
(Buzzi et al., 1992
), supporting a functional difference between
intracranial and extracranial MCs.
We were not able to directly investigate the effect of
N
-mH on histamine release due to the high
background resulting from cross-reactivity of the primary
anti-histamine antibody with the N
-mH added
during the perfusion. Reversed phase HPLC and a radioenzymatic assay
could distinguish histamine from mH, but the sensitivity was at least
10-fold lower than with the RIA kit and could not detect histamine in
the perfusate. An apparent regulatory effect of
H3 receptor ligands on histamine release,
however, was suggested by the fact that the H3
receptor antagonist Th increased brain histamine release stimulated
with either C48/80 or high K+; this peramide also
increased the morphological changes evident with C48/80. Th had no
effect on peritoneal MCs as previously reported for adenoidal MC
secretion (Bent et al., 1991
). These results imply that Th may be
releasing some tonal inhibitory action of brain histamine. The
inhibitory effect of H3 receptor agonists on the
release of [3H]histamine from cerebral cortex
slices loaded with [H3] histidine reported
previously was possible because histaminergic neurons have high
histidine decarboxylase activity (Pollard et al., 1976
; Panula et al.,
1984
). Inhibition of [3H]histamine release by
electrical stimulation (Van der Werf et al., 1987
) or high
K+ was also maximal at
10
6 M exogenous histamine as reported here.
Exogenous histamine also inhibited [3H]5-HT
release from electrically stimulated rat brain cortex slices (Fink et
al., 1990
) where Th increased monoamine release. The MCs in the
thalamic-hypothalamic area, however, have low histidine decarboxylase
activity and do not depolarize (Pollard et al., 1976
). They would not,
therefore, synthesize adequate radiolabeled histamine for detection
after stimulation with C48/80. Moreover, C48/80 previously used to
stimulate hypothalamic MCs apparently impaired synthesis of
[3H]histamine from
[3H]histidine (Verdiere et al., 1975
), making
radioactive histamine detection inappropriate for our experiments.
The importance of brain MCs was reviewed recently (Theoharides, 1996
;
Kines and Powell, 1997
). Mediators secreted from perivascular meningeal
MCs (Dimitriadou et al., 1992
) could contribute to the pathophysiology
of migraines and cluster headaches (Theoharides, 1983
). For instance,
MCs close to nerve fibers from the temporal artery showed
ultrastructural changes indicative of secretion only in the affected
side of patients with cluster headache (Liberski and Mirecka, 1984
).
Moreover, dura MCs degranulated in response to acute psychological
stress (Theoharides et al., 1995
), which is known to trigger or worsen
migraines. Little is known about the distribution or function of
H3 receptors or human cells. One study suggested
that much longer preincubation with H3 agonists was required to inhibit human monocyte function compared with rat MCs
(Bissonnette, 1996
). H3 receptor agonists might
be useful as prophylactic agents by reducing the release of brain MCs
and neuronal vasoactive molecules.
| |
Acknowledgments |
|---|
We thank Dr. M. Moskowitz (Massachusetts General Hospital, Boston, MA) for the Th and Linda Tamulaites and Sharon Titus for their word processing skills.
| |
Footnotes |
|---|
Accepted for publication April 29, 1999.
Received for publication November 3, 1998.
1 This work was supported by a grant from Kos Pharmaceuticals (Miami, FL).
2 The possible therapeutic use of H3 agonists in the treatment of migraines is covered by U.S. Patent 5,855,884 awarded to T.C.T.
3 Present address: Department of Neurology, Medical Academy, Lodz 90153, Poland.
4 Present address: Department of Neurosurgery, Cornell Medical College, Cornell, NY 10021.
5 Present address: Department of Surgery, New England Medical Center, Boston, MA 02111.
6 Present address: Department of Emergency Medicine, Langley Air Force Base, Hampton, VA 23665.
Send reprint requests to: T. C. Theoharides, Ph.D., M.D., Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111. E-mail: ttheoharides{at}infonet.tufts.edu
| |
Abbreviations |
|---|
CNS, central nervous system;
C48/80, compound
48/80;
CTMC, connective tissue mast cell;
H3, histamine 3;
5-HT, 5-hydroxytryptamine (serotonin);
IMI, imipramine;
KRB, Krebs-Ringer bicarbonate buffer;
LDH, lactic dehydrogenase;
MC, mast cell;
mH, methylhistamine;
MS, multiple sclerosis;
N
-mH, N
-methylhistamine;
RIA, radioimmunoassay;
Th, thioperamide;
TNF, tumor necrosis factor.
| |
References |
|---|
|
|
|---|
release by mast cells through H2 and H3 receptors.
Am J Respir Cell Mol Biol
14:
620-626[Abstract].
)-
-methyl-histamine and SMS 201-995 block plasma protein leakage within dura mater by prejunctional mechanisms.
Eur J Pharmacol
224:
145-150[Medline].
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||